Jocelyn Chan

1.5k total citations
11 papers, 555 citations indexed

About

Jocelyn Chan is a scholar working on Molecular Biology, Oncology and Computational Theory and Mathematics. According to data from OpenAlex, Jocelyn Chan has authored 11 papers receiving a total of 555 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 6 papers in Oncology and 2 papers in Computational Theory and Mathematics. Recurrent topics in Jocelyn Chan's work include Melanoma and MAPK Pathways (9 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jocelyn Chan is often cited by papers focused on Melanoma and MAPK Pathways (9 papers), PI3K/AKT/mTOR signaling in cancer (3 papers) and Cytokine Signaling Pathways and Interactions (3 papers). Jocelyn Chan collaborates with scholars based in United States and France. Jocelyn Chan's co-authors include Marcia Belvin, Klaus P. Hoeflich, Lori S. Friedman, Leanne Berry, Mark Merchant, Christine Orr, Edna F. Choo, Ian Kasman, Nai-Ying Yang and Hartmut Koeppen and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Cancer Research.

In The Last Decade

Jocelyn Chan

11 papers receiving 530 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jocelyn Chan United States 8 455 212 98 86 59 11 555
Zoi Karoulia United States 6 560 1.2× 238 1.1× 115 1.2× 130 1.5× 57 1.0× 9 664
T. Ahmad United Kingdom 7 566 1.2× 388 1.8× 82 0.8× 78 0.9× 77 1.3× 12 677
Vivienne Marsh United States 5 445 1.0× 220 1.0× 65 0.7× 106 1.2× 164 2.8× 5 648
Mary Ellen Simcox United States 8 458 1.0× 351 1.7× 96 1.0× 111 1.3× 95 1.6× 12 643
Kazuhiro Ohara Japan 4 346 0.8× 138 0.7× 53 0.5× 85 1.0× 36 0.6× 6 407
Matthew Zubrowski United States 5 506 1.1× 266 1.3× 76 0.8× 121 1.4× 24 0.4× 6 624
Jeff Kucharski United States 6 534 1.2× 216 1.0× 42 0.4× 46 0.5× 86 1.5× 10 656
Robert H. Sinnamon United States 6 510 1.1× 141 0.7× 66 0.7× 38 0.4× 35 0.6× 7 566
Jason Boggs United States 10 441 1.0× 145 0.7× 59 0.6× 64 0.7× 74 1.3× 15 572
Ann Palladino United States 4 352 0.8× 109 0.5× 75 0.8× 39 0.5× 32 0.5× 5 524

Countries citing papers authored by Jocelyn Chan

Since Specialization
Citations

This map shows the geographic impact of Jocelyn Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jocelyn Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jocelyn Chan more than expected).

Fields of papers citing papers by Jocelyn Chan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jocelyn Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jocelyn Chan. The network helps show where Jocelyn Chan may publish in the future.

Co-authorship network of co-authors of Jocelyn Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Jocelyn Chan. A scholar is included among the top collaborators of Jocelyn Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jocelyn Chan. Jocelyn Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Chan, Jocelyn, Lily Shao, Scott Stawicki, et al.. (2022). Systematic pharmacological analysis of agonistic and antagonistic fibroblast growth factor receptor 1 MAbs reveals a similar unique mode of action. Journal of Biological Chemistry. 299(1). 102729–102729. 1 indexed citations
2.
Dogan, Taner, Florian Gnad, Jocelyn Chan, et al.. (2017). Role of the E3 ubiquitin ligase RNF157 as a novel downstream effector linking PI3K and MAPK signaling pathways to the cell cycle. Journal of Biological Chemistry. 292(35). 14311–14324. 19 indexed citations
3.
Kirouac, Daniel C., Gabriele Schaefer, Jocelyn Chan, et al.. (2017). Clinical responses to ERK inhibition in BRAF V600E-mutant colorectal cancer predicted using a computational model. npj Systems Biology and Applications. 3(1). 14–14. 50 indexed citations
4.
Choo, Edna F., Justin Q. Ly, Jocelyn Chan, et al.. (2014). Role of P-Glycoprotein on the Brain Penetration and Brain Pharmacodynamic Activity of the MEK Inhibitor Cobimetinib. Molecular Pharmaceutics. 11(11). 4199–4207. 41 indexed citations
5.
Merchant, Mark, Jocelyn Chan, Jin Cheng, et al.. (2014). 387 Combination of the ERK inhibitor GDC-0994 with the MEK inhibitor cobimetinib significantly enhances anti-tumor activity in KRAS and BRAF mutant tumor models. European Journal of Cancer. 50. 124–124. 7 indexed citations
6.
Kirkpatrick, Donald S., Daisy Bustos, Taner Dogan, et al.. (2013). Phosphoproteomic characterization of DNA damage response in melanoma cells following MEK/PI3K dual inhibition. Proceedings of the National Academy of Sciences. 110(48). 19426–19431. 44 indexed citations
7.
Heald, Robert A., Philip S. Jackson, Pascal Savy, et al.. (2012). Discovery of Novel Allosteric Mitogen-Activated Protein Kinase Kinase (MEK) 1,2 Inhibitors Possessing Bidentate Ser212 Interactions. Journal of Medicinal Chemistry. 55(10). 4594–4604. 31 indexed citations
8.
Hoeflich, Klaus P., Mark Merchant, Christine Orr, et al.. (2011). Intermittent Administration of MEK Inhibitor GDC-0973 plus PI3K Inhibitor GDC-0941 Triggers Robust Apoptosis and Tumor Growth Inhibition. Cancer Research. 72(1). 210–219. 200 indexed citations
9.
Choo, Edna F., Marcia Belvin, Jocelyn Chan, et al.. (2010). Preclinical disposition and pharmacokinetics-pharmacodynamic modeling of biomarker response and tumour growth inhibition in xenograft mouse models of G-573, a MEK inhibitor. Xenobiotica. 40(11). 751–762. 17 indexed citations
10.
11.
Hoeflich, Klaus P., Mark Merchant, Jocelyn Chan, et al.. (2009). Abstract A250: Preclinical combination efficacy and identification of biomarkers of MEK and PI3K inhibitors in phase I. Molecular Cancer Therapeutics. 8(12_Supplement). A250–A250. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Zoi Karoulia Breakdown of academic impact, for papers by T. Ahmad Breakdown of academic impact, for papers by Vivienne Marsh Breakdown of academic impact, for papers by Mary Ellen Simcox Breakdown of academic impact, for papers by Kazuhiro Ohara Breakdown of academic impact, for papers by Matthew Zubrowski Breakdown of academic impact, for papers by Jeff Kucharski Breakdown of academic impact, for papers by Robert H. Sinnamon Breakdown of academic impact, for papers by Jason Boggs Breakdown of academic impact, for papers by Ann Palladino
Rankless by CCL
2026